Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

Inclusion Criteria:

Subjects must give a written, signed and dated informed consent
Chronic plaque-type psoriasis present for at least 6 months before randomization

Moderate to severe plaque psoriasis as defined at randomization by:

PASI score of ≥12 and
Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% and
IGA mod 2011 ≥3 (based on a scale of 0-4)

Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:

Topical treatment (including topical corticosteroids) and/or
Phototherapy and/or
Previous systemic therapy

Exclusion Criteria:

Forms of psoriasis other than plaque psoriasis
Drug-induced psoriasis
Ongoing use of prohibited treatments
Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA, or ustekinumab, or any therapies targeting IL-12 or IL-23
Use of any other investigational drugs within 5 half-lives of the investigational treatment before study drug initiation
Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply